Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle

Imke H. Bartelink, Ella F. Jones, Sheerin K. Shahidi-Latham, Pei Rong Evelyn Lee, Yanan Zheng, Paolo Vicini, Laura van ‘t Veer, Denise Wolf, Andrei Iagaru, Deanna L. Kroetz, Brendan Prideaux, Cornelius Cilliers, Greg M. Thurber, Zena Wimana, Geraldine Gebhart

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Precision medicine aims to use patient genomic, epigenomic, specific drug dose, and other data to define disease patterns that may potentially lead to an improved treatment outcome. Personalized dosing regimens based on tumor drug penetration can play a critical role in this approach. State-of-the-art techniques to measure tumor drug penetration focus on systemic exposure, tissue penetration, cellular or molecular engagement, and expression of pharmacological activity. Using in silico methods, this information can be integrated to bridge the gap between the therapeutic regimen and the pharmacological link with clinical outcome. These methodologies are described, and challenges ahead are discussed. Supported by many examples, this review shows how the combination of these techniques provides enhanced patient-specific information on drug accessibility at the tumor tissue level, target binding, and downstream pharmacology. Our vision of how to apply tumor drug penetration measurements offers a roadmap for the clinical implementation of precision dosing.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
Pharmacology
Neoplasms
Therapeutics
Precision Medicine
Epigenomics
Computer Simulation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Bartelink, I. H., Jones, E. F., Shahidi-Latham, S. K., Lee, P. R. E., Zheng, Y., Vicini, P., ... Gebhart, G. (Accepted/In press). Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.1211

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. / Bartelink, Imke H.; Jones, Ella F.; Shahidi-Latham, Sheerin K.; Lee, Pei Rong Evelyn; Zheng, Yanan; Vicini, Paolo; van ‘t Veer, Laura; Wolf, Denise; Iagaru, Andrei; Kroetz, Deanna L.; Prideaux, Brendan; Cilliers, Cornelius; Thurber, Greg M.; Wimana, Zena; Gebhart, Geraldine.

In: Clinical Pharmacology and Therapeutics, 01.01.2018.

Research output: Contribution to journalArticle

Bartelink, IH, Jones, EF, Shahidi-Latham, SK, Lee, PRE, Zheng, Y, Vicini, P, van ‘t Veer, L, Wolf, D, Iagaru, A, Kroetz, DL, Prideaux, B, Cilliers, C, Thurber, GM, Wimana, Z & Gebhart, G 2018, 'Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle', Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.1211
Bartelink, Imke H. ; Jones, Ella F. ; Shahidi-Latham, Sheerin K. ; Lee, Pei Rong Evelyn ; Zheng, Yanan ; Vicini, Paolo ; van ‘t Veer, Laura ; Wolf, Denise ; Iagaru, Andrei ; Kroetz, Deanna L. ; Prideaux, Brendan ; Cilliers, Cornelius ; Thurber, Greg M. ; Wimana, Zena ; Gebhart, Geraldine. / Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. In: Clinical Pharmacology and Therapeutics. 2018.
@article{f659c145f2f44a4d8836a982584002c3,
title = "Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle",
abstract = "Precision medicine aims to use patient genomic, epigenomic, specific drug dose, and other data to define disease patterns that may potentially lead to an improved treatment outcome. Personalized dosing regimens based on tumor drug penetration can play a critical role in this approach. State-of-the-art techniques to measure tumor drug penetration focus on systemic exposure, tissue penetration, cellular or molecular engagement, and expression of pharmacological activity. Using in silico methods, this information can be integrated to bridge the gap between the therapeutic regimen and the pharmacological link with clinical outcome. These methodologies are described, and challenges ahead are discussed. Supported by many examples, this review shows how the combination of these techniques provides enhanced patient-specific information on drug accessibility at the tumor tissue level, target binding, and downstream pharmacology. Our vision of how to apply tumor drug penetration measurements offers a roadmap for the clinical implementation of precision dosing.",
author = "Bartelink, {Imke H.} and Jones, {Ella F.} and Shahidi-Latham, {Sheerin K.} and Lee, {Pei Rong Evelyn} and Yanan Zheng and Paolo Vicini and {van ‘t Veer}, Laura and Denise Wolf and Andrei Iagaru and Kroetz, {Deanna L.} and Brendan Prideaux and Cornelius Cilliers and Thurber, {Greg M.} and Zena Wimana and Geraldine Gebhart",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cpt.1211",
language = "English (US)",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle

AU - Bartelink, Imke H.

AU - Jones, Ella F.

AU - Shahidi-Latham, Sheerin K.

AU - Lee, Pei Rong Evelyn

AU - Zheng, Yanan

AU - Vicini, Paolo

AU - van ‘t Veer, Laura

AU - Wolf, Denise

AU - Iagaru, Andrei

AU - Kroetz, Deanna L.

AU - Prideaux, Brendan

AU - Cilliers, Cornelius

AU - Thurber, Greg M.

AU - Wimana, Zena

AU - Gebhart, Geraldine

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Precision medicine aims to use patient genomic, epigenomic, specific drug dose, and other data to define disease patterns that may potentially lead to an improved treatment outcome. Personalized dosing regimens based on tumor drug penetration can play a critical role in this approach. State-of-the-art techniques to measure tumor drug penetration focus on systemic exposure, tissue penetration, cellular or molecular engagement, and expression of pharmacological activity. Using in silico methods, this information can be integrated to bridge the gap between the therapeutic regimen and the pharmacological link with clinical outcome. These methodologies are described, and challenges ahead are discussed. Supported by many examples, this review shows how the combination of these techniques provides enhanced patient-specific information on drug accessibility at the tumor tissue level, target binding, and downstream pharmacology. Our vision of how to apply tumor drug penetration measurements offers a roadmap for the clinical implementation of precision dosing.

AB - Precision medicine aims to use patient genomic, epigenomic, specific drug dose, and other data to define disease patterns that may potentially lead to an improved treatment outcome. Personalized dosing regimens based on tumor drug penetration can play a critical role in this approach. State-of-the-art techniques to measure tumor drug penetration focus on systemic exposure, tissue penetration, cellular or molecular engagement, and expression of pharmacological activity. Using in silico methods, this information can be integrated to bridge the gap between the therapeutic regimen and the pharmacological link with clinical outcome. These methodologies are described, and challenges ahead are discussed. Supported by many examples, this review shows how the combination of these techniques provides enhanced patient-specific information on drug accessibility at the tumor tissue level, target binding, and downstream pharmacology. Our vision of how to apply tumor drug penetration measurements offers a roadmap for the clinical implementation of precision dosing.

UR - http://www.scopus.com/inward/record.url?scp=85054505918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054505918&partnerID=8YFLogxK

U2 - 10.1002/cpt.1211

DO - 10.1002/cpt.1211

M3 - Article

C2 - 30107040

AN - SCOPUS:85054505918

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -